Immunohistochemical expression of glutathione S-transferase-π can predict chemotherapy response in patients with nonsmall cell lung carcinoma

Fen Bai, Yoichi Nakanishi, Masayuki Kawasaki, Koichi Takayama, Jun Yatsunami, Xin Hai Pei, Nobuko Tsuruta, Kentaro Wakamatsu, Nobuyuki Hara

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

BACKGROUND. Resistance to chemotherapy agents is a major problem in the treatment of patients with nonsmall cell lung carcinoma (NSCLC). Recent studies have indicated that glutathione S-transferase-π (GST-π) may play an important role in the resistance of cancer cells to alkylating agents, including cisplatin compounds. METHODS. The expression of GST-π in tissues obtained by bronchoscopic biopsy from 38 NSCLC patients was investigated immunohistochemically. These patients were treated with a combination of cisplatin-based chemotherapy and were evaluated to determine the relationship between GST-π expression and chemotherapy response. RESULTS. Of the 38 patients, 25 (66%) were GST-π-positive and 13 (34%) were negative. There was no significant correlation between GST-π expression and the clinicopathologic factors examined (age, sex, performance status, histology, differentiation grade, and stage). Of the 38 patients treated with cisplatin- based chemotherapy, 12 patients responded to chemotherapy (overall response rate, 32%). For the patients with negative GST-π expression, the response rate was 89% (9 of 13 patients). In the patients with positive GST-π expression, the response rate was 12% (3 of 25 patients). This difference was statistically significant (P = 0.0012). CONCLUSIONS. The expression of GST- π in NSCLC patients was significantly related to response to cisplatin- based chemotherapy, and may be a useful predictor of chemotherapy response.

Original languageEnglish
Pages (from-to)416-421
Number of pages6
JournalCancer
Volume78
Issue number3
DOIs
Publication statusPublished - Aug 1 1996

Fingerprint

Glutathione Transferase
Carcinoma
Drug Therapy
Lung
Cisplatin
Alkylating Agents
Age Factors
Histology
Biopsy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Immunohistochemical expression of glutathione S-transferase-π can predict chemotherapy response in patients with nonsmall cell lung carcinoma. / Bai, Fen; Nakanishi, Yoichi; Kawasaki, Masayuki; Takayama, Koichi; Yatsunami, Jun; Pei, Xin Hai; Tsuruta, Nobuko; Wakamatsu, Kentaro; Hara, Nobuyuki.

In: Cancer, Vol. 78, No. 3, 01.08.1996, p. 416-421.

Research output: Contribution to journalArticle

Bai, Fen ; Nakanishi, Yoichi ; Kawasaki, Masayuki ; Takayama, Koichi ; Yatsunami, Jun ; Pei, Xin Hai ; Tsuruta, Nobuko ; Wakamatsu, Kentaro ; Hara, Nobuyuki. / Immunohistochemical expression of glutathione S-transferase-π can predict chemotherapy response in patients with nonsmall cell lung carcinoma. In: Cancer. 1996 ; Vol. 78, No. 3. pp. 416-421.
@article{37bea147aff24e4587f8f290220f60e6,
title = "Immunohistochemical expression of glutathione S-transferase-π can predict chemotherapy response in patients with nonsmall cell lung carcinoma",
abstract = "BACKGROUND. Resistance to chemotherapy agents is a major problem in the treatment of patients with nonsmall cell lung carcinoma (NSCLC). Recent studies have indicated that glutathione S-transferase-π (GST-π) may play an important role in the resistance of cancer cells to alkylating agents, including cisplatin compounds. METHODS. The expression of GST-π in tissues obtained by bronchoscopic biopsy from 38 NSCLC patients was investigated immunohistochemically. These patients were treated with a combination of cisplatin-based chemotherapy and were evaluated to determine the relationship between GST-π expression and chemotherapy response. RESULTS. Of the 38 patients, 25 (66{\%}) were GST-π-positive and 13 (34{\%}) were negative. There was no significant correlation between GST-π expression and the clinicopathologic factors examined (age, sex, performance status, histology, differentiation grade, and stage). Of the 38 patients treated with cisplatin- based chemotherapy, 12 patients responded to chemotherapy (overall response rate, 32{\%}). For the patients with negative GST-π expression, the response rate was 89{\%} (9 of 13 patients). In the patients with positive GST-π expression, the response rate was 12{\%} (3 of 25 patients). This difference was statistically significant (P = 0.0012). CONCLUSIONS. The expression of GST- π in NSCLC patients was significantly related to response to cisplatin- based chemotherapy, and may be a useful predictor of chemotherapy response.",
author = "Fen Bai and Yoichi Nakanishi and Masayuki Kawasaki and Koichi Takayama and Jun Yatsunami and Pei, {Xin Hai} and Nobuko Tsuruta and Kentaro Wakamatsu and Nobuyuki Hara",
year = "1996",
month = "8",
day = "1",
doi = "10.1002/(SICI)1097-0142(19960801)78:3<416::AID-CNCR6>3.0.CO;2-H",
language = "English",
volume = "78",
pages = "416--421",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Immunohistochemical expression of glutathione S-transferase-π can predict chemotherapy response in patients with nonsmall cell lung carcinoma

AU - Bai, Fen

AU - Nakanishi, Yoichi

AU - Kawasaki, Masayuki

AU - Takayama, Koichi

AU - Yatsunami, Jun

AU - Pei, Xin Hai

AU - Tsuruta, Nobuko

AU - Wakamatsu, Kentaro

AU - Hara, Nobuyuki

PY - 1996/8/1

Y1 - 1996/8/1

N2 - BACKGROUND. Resistance to chemotherapy agents is a major problem in the treatment of patients with nonsmall cell lung carcinoma (NSCLC). Recent studies have indicated that glutathione S-transferase-π (GST-π) may play an important role in the resistance of cancer cells to alkylating agents, including cisplatin compounds. METHODS. The expression of GST-π in tissues obtained by bronchoscopic biopsy from 38 NSCLC patients was investigated immunohistochemically. These patients were treated with a combination of cisplatin-based chemotherapy and were evaluated to determine the relationship between GST-π expression and chemotherapy response. RESULTS. Of the 38 patients, 25 (66%) were GST-π-positive and 13 (34%) were negative. There was no significant correlation between GST-π expression and the clinicopathologic factors examined (age, sex, performance status, histology, differentiation grade, and stage). Of the 38 patients treated with cisplatin- based chemotherapy, 12 patients responded to chemotherapy (overall response rate, 32%). For the patients with negative GST-π expression, the response rate was 89% (9 of 13 patients). In the patients with positive GST-π expression, the response rate was 12% (3 of 25 patients). This difference was statistically significant (P = 0.0012). CONCLUSIONS. The expression of GST- π in NSCLC patients was significantly related to response to cisplatin- based chemotherapy, and may be a useful predictor of chemotherapy response.

AB - BACKGROUND. Resistance to chemotherapy agents is a major problem in the treatment of patients with nonsmall cell lung carcinoma (NSCLC). Recent studies have indicated that glutathione S-transferase-π (GST-π) may play an important role in the resistance of cancer cells to alkylating agents, including cisplatin compounds. METHODS. The expression of GST-π in tissues obtained by bronchoscopic biopsy from 38 NSCLC patients was investigated immunohistochemically. These patients were treated with a combination of cisplatin-based chemotherapy and were evaluated to determine the relationship between GST-π expression and chemotherapy response. RESULTS. Of the 38 patients, 25 (66%) were GST-π-positive and 13 (34%) were negative. There was no significant correlation between GST-π expression and the clinicopathologic factors examined (age, sex, performance status, histology, differentiation grade, and stage). Of the 38 patients treated with cisplatin- based chemotherapy, 12 patients responded to chemotherapy (overall response rate, 32%). For the patients with negative GST-π expression, the response rate was 89% (9 of 13 patients). In the patients with positive GST-π expression, the response rate was 12% (3 of 25 patients). This difference was statistically significant (P = 0.0012). CONCLUSIONS. The expression of GST- π in NSCLC patients was significantly related to response to cisplatin- based chemotherapy, and may be a useful predictor of chemotherapy response.

UR - http://www.scopus.com/inward/record.url?scp=0029895149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029895149&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19960801)78:3<416::AID-CNCR6>3.0.CO;2-H

DO - 10.1002/(SICI)1097-0142(19960801)78:3<416::AID-CNCR6>3.0.CO;2-H

M3 - Article

VL - 78

SP - 416

EP - 421

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -